Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →Gland Pharma Limited — Q4 FY25
Gland Pharma's Q4 FY25 consolidated revenue was INR 1,424.9 crore with EBITDA of INR 347.5 crore (24% margin, +100bps YoY).
neutral
medium
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Gland Pharma's Q4 FY25 consolidated revenue was INR 1,424.9 crore with EBITDA of INR 347.5 crore (24% margin, +100bps YoY). Base business (ex-Cenexi) revenue declined 12% YoY to INR 1,033.2 crore due to high base and tender losses, but EBITDA margin improved to 38% (+200bps YoY) on better product mix and cost controls. Cenexi revenue was EUR 43 million, impacted by remediation and equipment breakdowns, though gross margin improved to 79%. Management guided for mid-teens consolidated revenue growth in FY26, driven by new launches, CMO contracts, and biologics (INR 100 crore expected). Key risks include Cenexi turnaround delays and U.S. tariff uncertainty, though management believes generics will be less impacted. The company is scaling GLP-1 cartridge capacity from 40M to 140M units by CY26, with two contracts secured.
ग्लैंड फार्मा की चौथी तिमाही (जनवरी-मार्च 2025) की कुल कमाई 1,424.9 करोड़ रुपये रही। कंपनी ने 347.5 करोड़ रुपये का EBITDA (कमाई में से खर्च घटाने के बाद बचा मुनाफा) कमाया, जो 24% मार्जिन है और पिछले साल से 1% ज्यादा है। मुख्य कारोबार (Cenexi को छोड़कर) की कमाई 12% घटकर 1,033.2 करोड़ रुपये रही, क्योंकि पिछले साल का आधार ऊंचा था और कुछ टेंडर हार गए। लेकिन बेहतर उत्पाद मिश्रण और खर्च नियंत्रण से मार्जिन 38% हो गया। Cenexi की कमाई 43 मिलियन यूरो रही, जो मरम्मत और मशीन खराब होने से प्रभावित हुई। कंपनी को FY26 में 14-15% कमाई बढ़ने की उम्मीद है, नए उत्पादों और बायोलॉजिक्स से। जोखिमों में Cenexi की सुधार में देरी और अमेरिकी टैरिफ अनिश्चितता शामिल है। कंपनी GLP-1 कार्ट्रिज क्षमता 4 करोड़ से 14 करोड़ यूनिट तक बढ़ा रही है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Risks
4 risks
Risk Intelligence
Cenexi turnaround execution risk
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
U.S. volume growth (FY25)
9%
+9% YoY
Volume growth in the U.S. market for FY25, driven by new launches and increased market share.
New product gross margin (U.S.)
72%
+14pp vs company average
Gross margin on new U.S. launches is significantly higher than the company average of 58%.
Cenexi order book
EUR 100M
N/A
Cenexi's current order book stands at EUR 100 million, providing visibility into future revenue.
GLP-1 cartridge capacity (CY26 target)
140M units
+100M vs current
Gland is expanding cartridge capacity from 40M to 140M units by CY26 to meet GLP-1 demand.
What Changed vs Last Quarter
NEW
Mid-teens consolidated revenue growth in FY26
Management expects consolidated revenue to grow in the mid-teens percentage range in FY26, driven by new launches, CMO projects, and biologics.
NEW
GLP-1 cartridge capacity expansion to 140M units by CY26
Gland is adding 100 million units of cartridge capacity, reaching 140 million units total by calendar year 2026, to support GLP-1 contracts.
UPDATED
Cenexi positive EBITDA by Q3 FY26
Cenexi is targeting to achieve positive EBITDA by the third quarter of FY26, with double-digit EBITDA margins expected in FY27.
UPDATED
Biologics revenue of INR 100 crore in FY26
The biologics segment, including the Dr. Reddy's collaboration, is expected to contribute approximately INR 100 crore in revenue in FY26.
DROPPED
Cenexi revenue run rate of EUR 15M per quarter
Management targets Cenexi quarterly revenue above EUR 15 million to support EBITDA breakeven, driven by new high-speed lines.
DROPPED
15KL additional biologics capacity for Henlius
Planned expansion of biologics drug substance capacity by 15KL to support the Shanghai Henlius collaboration, with revenue likely from FY27-28.
NEW RISK
Cenexi turnaround execution risk
Cenexi's performance has been below expectations, with losses persisting due to remediation activities and equipment breakdowns. Achieving positive EBITDA by Q3 FY26 is uncertain.
NEW RISK
U.S. tariff impact on generics
The U.S. administration's reciprocal tariffs create uncertainty for Indian pharma companies. While management expects minimal impact on generics, the situation remains fluid.
NEW RISK
ROW market tender losses
The ROW segment saw a 14% revenue decline in Q4 due to tender misses and softer offtake. Recovery depends on re-engaging local partners and executing a non-Enoxa strategy.
NEW RISK
Cenexi capital allocation concerns
Analysts questioned the return on invested capital for Cenexi, given the high acquisition cost and additional capex. Management's target of 18% EBITDA on $300M revenue may still yield suboptimal ROCE.
RISK GONE
Cenexi regulatory delays
Unannounced ANSM inspection at Fontenay caused production loss and corrective measures, pushing EBITDA breakeven to Q3 FY26. Further regulatory actions could delay recovery.
RISK GONE
Volume recovery in US base business
Base business revenue declined 8% YoY due to volume degrowth in key products like Enoxaparin. Recovery depends on timing of shipments and new product ramp-up.
RISK GONE
Saudi tender revenue deferral
The Saudi tender shipment was pushed out by a quarter, impacting Q3 revenue. Further delays could affect near-term ROW growth.
RISK GONE
Chinese competition and tariff uncertainty
Chinese players control 50-60% of Heparin API supply. While US tariffs may benefit Gland, raw material dependence on China remains a risk.
🤫 Topics management stopped discussing
Mentioned in Q1 FY24, Q2 FY25, Q3 FY24, Q3 FY25, Q4 FY24
Unannounced ANSM inspection at Fontenay caused production loss and corrective measures, pushing EBITDA breakeven to Q3 FY26. Further regulatory actions could delay recovery.
Mentioned in Q1 FY25, Q2 FY24, Q3 FY24
Management guided base business EBITDA margin in the range of 30-33% for the full year.
Mentioned in Q2 FY25, Q3 FY24, Q3 FY25
Cenexi is expected to achieve positive EBITDA by Q3 FY26, delayed from earlier Q4 FY25 guidance due to ANSM inspection impact.
Mentioned in Q2 FY24, Q3 FY24, Q3 FY25
Management targets Cenexi quarterly revenue above EUR 15 million to support EBITDA breakeven, driven by new high-speed lines.
Mentioned in Q1 FY25, Q4 FY24
Management expects base business (ex-Cenexi) to grow in mid-teens for the full fiscal year.
Fast read
Guidance and risk preview
Management expects consolidated revenue to grow in the mid-teens percentage range in FY26, driven by new launches, CMO projects, and biologics.
Cenexi's performance has been below expectations, with losses persisting due to remediation activities and equipment breakdowns.
View Risks →